Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amakem has got EUR1.28m by the Flemish government agency for Innovation by Science and Technology (IWT) to support its Rho kinase (ROCK) inhibitor-based drug development program for chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
Amakem focuses on making drugs safer by limiting or avoiding systemic exposure, thereby reducing side effects caused in non target organs.
Amakem CSO Dirk Leysen said that they developed the Localised Drug Action based ROCK inhibitors to tackle both inflammation as well as bronchoconstriction in COPD without causing cardiovascular or other side effects.
"In this way we offer an alternative and safe approach to render kinase targets drugable," Leysen said said.
Amakem CEO said that this government grant enables Amakem to advance its COPD program more rapidly, but it also acknowledges the quality of our COPD program.
"Our kinase inhibitors have the potential to really deal with inflammation in COPD and thereby become a breakthrough therapy to stop disease progression."